Ando, Apigyn P.

HRN: 07-94-01  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/28/2022
CEFUROXIME 750MG (VIAL)
04/28/2022
04/29/2022
IV
3 Doses
Q8
S/P Repeat CS With Bilateral Tubal Ligation
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: No  Wrong Dose  Increase Dose To 1.5g

Overall appropriateness: No  Increase Dose To 1.5 G

Intervention



Type of Intervention done:

                    

           


Acceptance: